Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 4Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Multiple Myeloma 7Hematologic Neoplasms 7Graft vs Host Disease 5Gliosarcoma 5Glioblastoma 5Brain Neoplasms 5Prostatic Neoplasms 4Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Waldenstrom Macroglobulinemia 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3Tuberous Sclerosis 2Oligodendroglioma 2Neurofibrosarcoma 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma 2Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Glioma 2Burkitt Lymphoma 2Bronchiolitis Obliterans Syndrome 2

Interventions

pembrolizumab 74Nivolumab 53Ipilimumab 42Cyclophosphamide 32Interleukin-2 24aldesleukin 23Temozolomide 17fludarabine 16Biopsy 11trametinib 10fludarabine phosphate 10dabrafenib 10spartalizumab 8Paclitaxel 8Dacarbazine 8sargramostim 7cemiplimab 7binimetinib 7Cisplatin 7Bevacizumab 7poly ICLC 6lenvatinib 6epacadostat 6Radiotherapy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5encorafenib 5atezolizumab 5Vemurafenib 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Melanoma × Sirolimus × Clear all
NCT05896839 2026-05-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
16 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡